Diem Nguyen is Chief Executive Officer and Director at SIGA. She was appointed in January 2024. Most recently, Dr. Nguyen served as CEO of Xalud Therapeutics, a clinical stage biotechnology company developing treatments for inflammatory diseases.

SIGA is a leader in global health, developing medicines to prevent and treat emerging infectious diseases with high unmet medical needs. Infectious diseases pose an imminent and severe threat to global health that cannot be adequately addressed with vaccines alone.

2024年1月22日 · SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen , Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024 , and will also be appointed to the Company’s Board of Directors.

2024年1月23日 · SIGA Technologies has appointed Dr Diem Nguyen as its new chief executive officer (CEO), effective 27 January 2024. She will be spearheading the company efforts to expand its commercial operations, following the retirement of incumbent CEO, Dr Phil Gomez (who had announced plans to retire in January 2023).

Diem Nguyen has more than 25 years of experience and extensive expertise in the pharmaceutical industry. She is currently the CEO of SIGA Technologies, a public commercial stage pharmaceutical company focused on anti-viral treatments.

Diem Nguyen is Chief Executive Officer and Director at SIGA. She was appointed in January 2024. Most recently, Dr. Nguyen served as CEO of Xalud Therapeutics, a clinical stage biotechnology company developing treatments for inflammatory diseases.

NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company’s Board of ...

2024年1月22日 · Dr. Nguyen joins SIGA from Xalud Therapeutics, a clinical stage biotechnology company developing treatments for inflammatory diseases, including pain associated with osteoarthritis, and ...

NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced...

2024年1月22日 · 商业舞台制药公司SIGA Technologies，Inc.（SIGA）周一表示，已任命Diem Nguyen为首席执行官，自1月27日起生效。 Nguyen将接替SIGA现任首席执行官Phil Gomez，Phil Gomez将于1月26日退休。